Tissue and Data Acquisition and Analysis Resource

确定基因表达中导致恶性表型的关键变化， 长期以来，这一直是基础和临床科学生物医学研究人员的目标。我们学到了很多 关于疾病机制使用模型系统（组织培养和动物），但翻译 在人类临床疾病模型系统中的发现并不理想。后者至少应在 部分原因是人类临床疾病的复杂性，这是由于大量的基因， 在细胞代谢中具有活性，以及与个体患者疾病相关的合并症， 改变或偏向疾病过程的表型。高通量检测方法的发展 例如用于测量基因表达的DMA芯片技术、染色体杂交和单个 核苷酸多态性部分地解决了细胞水平上的生物复杂性问题。 然而，获取可能影响患者结局的临床共病和治疗数据， 影响细胞代谢的变化更加困难，因为它依赖于各种人工记录， 报告系统。 组织和数据采集与分析核心（TDAAC）的目标是采集人体组织数据， 标本和相关的临床和病理结果，以支持目标的转化研究 疾病为此，它支持IRB批准的方案“支持癌症的组织采集系统” 研究”（TASSCR）以及其他研究者发起的IRB批准的方案，以支持特定的 调查问题。因为TDAAC是一个多中心资助的产物， 多个癌症表型的表达微阵列研究，一些样品具有相关基因 表达式数据作为其注释的一部分。TDAAC的教职员工通过以下方式支持翻译研究： 在高道德标准下利用患者知情的方法获取带注释的组织和血液样本 同意和处理标本，以便标本用于患者护理的主要目的是 标本的质量是生物医学研究的最佳选择。

Identification of critical changes in gene expression that are responsible for the malignant phenotype has long been the goal of biomedical researchers in the basic and clinical sciences. Much has been learned concerning disease mechanism using model systems (tissue culture and animals) but the translation of findings in model systems to human clinical disease has been less than optimal. The latter is due at least in part to the complexity of human clinical disease which results from the vast number of genes which are active in cellular metabolism and the co-morbidities associated with an individual patient's disease which can alter or bias the phenotype of the disease process. The development of high throughput testing methods such as DMA chip technologies for measuring gene expression, chromosomal hybridization and single nucleotide polymporphisms has in part addressed the issue of biological complexity at the cellular level. However, acquiring clinical co-morbidity and treatment data that is likely to affect patient outcome and may impact changes in cellular metabolism is more difficult as it relies on various manual human recording and reporting systems. The Tissue and Data Acquisition and Analysis Core (TDAAC) has as its goal the acquisition of human specimens and associated clinical and pathologic findings to support translational research of the target disease. To this end it supports an IRB approved protocol "Tissue Acquisition System to Support Cancer Research" (TASSCR) as well as other investigator initiated IRB approved protocols to support specific investigative questions. Because TDAAC is an outgrowth of a multicenter grant that focused on gene expression microarray studies on multiple cancer phenotypes, some samples have associated gene expression data as a part of their annotation. TDAAC faculty and staff support translational research through acquisition of annotated tissue and blood samples under high ethical standards utilizing patient informed consent and treatment of specimens such that the primary purpose of the specimen for patient care is maintained and the quality of the specimen is optimal for biomedical research.